1. A conjugate of growth hormone, comprising growth hormone compound (GH), comprising: a) introducing a single mutation with Cys, b) an additional disulfide bridge ilic) introducing a single mutation and an additional Cys disulfide bridge, the albumin-binding radical attached via a hydrophilic spacer to said GH, or a pharmaceutically acceptable sol.2. The conjugate of claim 1, wherein the growth hormone conjugate is of the formula (I): gdeGH compound is growth hormone, B represents a hydrophilic spacer, W is a chemical group linking A and B, iA represents albumin-binding radical and pharmaceutically acceptable soli.3. The conjugate of claim 1, wherein the hydrophilic spacer is associated with: a) N-terminus or Gln40 Gln141 or growth hormone compound or b) a sulfur atom in the introduction of single mutations Cys, present in a compound of growth hormone and selected from one of the following mutations: T3C, P5C, S7C, D11C, H18C, Q29C, E30C, E33C, A34C, Y35C, K38C, E39C, Y42C, S43C, D47C, P48C, S55C, S57C, P59C, S62, E65C, Q69C, E88C, Q91C, S95C, A98C, N99C, S100C, L101C, V102C, Y103C, D107C, S108C, D112C, Q122C, G126C, E129C, D130C, G131C, P133C, T135C, G136C, T142C, D147C, N149C, D154C, A155C, L156C, R178C, E186C, G187C and G190C, for example, from any one mutation of: T3C, P5C, S7C, D11C, H18C, Q29C, E30C, E33C, A34C, Y35C, E88C, Q91C, S95C, A98C, N99C, S100C, L101C, V102C, Y103C, D107C, S108C, D112C, Q122 G126C C and composed of hGH (SEQ ID NO: 1) .4. The conjugate of claim 1, wherein the GH includes an additional disulfide bridge between at least one pair of amino acids at positions corresponding R16C / L117C, A17C / E174C, H21C / M170C, D26C / V102C, D26C / Y103C, N47C / T50C, Q49C / G161C, F54C / Y143C, F54C / S144C, F54C / F146C, S55C / Y143C, S57C / Y143C, I58C / Q141C, I58C / Y143C, I58C / S144C, P59C / Q137C, P61C / E66C, P61C / T67C, S71C / S132C , L73C / S132C, L73C / F139C, R77C / I138C, R77C / F139C, L81C / Q141C, L81C / Y143C, Q84C / Y143C, Q84C / S144
